<DOC>
	<DOCNO>NCT02067611</DOCNO>
	<brief_summary>This phase 2 , multicenter , randomize , double blind ( dose ) , placebo control , parallel group , proof concept , dose range find study evaluate efficacy , safety , PK X0002 spray adult subject clinically symptomatic mild moderate OA knee . Objectives study : 1 . To evaluate efficacy X0002 spray compare placebo relief knee pain subject osteoarthritis ( OA ) knee ; 2 . To assess safety tolerability multiple dos X0002 administer topical spray .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety X0002 Spray Subjects With Osteoarthritis</brief_title>
	<detailed_description>This phase 2 , multicenter , randomize , double blind ( dose ) , placebo control , parallel group , proof concept , dose range find study evaluate efficacy , safety , PK X0002 spray adult subject clinically symptomatic mild moderate OA knee . After screen period 3 week radiographic evaluation target knee joint space , 225 subject randomly assign 1 3 treatment group 1:1:1 ratio 2:1 ratio active : placebo within treatment group 1:1:1 ratio 2:1 ratio active : placebo within treatment group ( i.e. , 2 subject active treatment 1 subject placebo ) : Group A : low dose X0002 , twice daily ( BID , approximately every 12 hour ; n=50 ) placebo ( low dose ) , BID ( approximately every 12 hour ; n=25 ) ; Group B : middle dose X0002 , BID ( approximately every 12 hour ; n=50 ) placebo , BID ( approximately every 12 hour ; n=25 ) ; Group C : High dose X0002 , BID ( approximately every 12 hour ; n=50 ) placebo , BID ( approximately every 12 hour ; n=25 ) . Safety efficacy assessment perform 2 , 4 , 8 , 12 week treatment .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<criteria>A subject must male female 35 85 year age , inclusive . A subject must body mass index ( BMI ) 18.5 39.9 kg/m2 , inclusive . A subject must diagnosis idiopathic OA accord American College Rheumatology ( ACR ) clinical radiographic criterion ( knee pain , osteophytes , least one following : &gt; 50 year age , morning stiffness last &lt; 30 minute get morning , crepitus ) . A subject must Kellgren Lawrence Grade 1 2 determine Investigator local radiologist Screening . A subject must history clinically symptomatic mild moderate OA knee ≥6 month . A subject must knee pain standing , walk , and/or motion least 14 day month prior Screening . A subject must knee pain score ≥40 mm &lt; 90 mm 100 mm VAS ( without analgesic medication ) least 10 14 day prior randomization . A subject must willing discontinue NSAIDs analgesic ( eg , aspirin , acetaminophen ) potentially confound concomitant treatment ( eg , physiotherapy , acupuncture ) start 4 day administration first dose study medication complete participation study . ( The use ≤325 mg acetylsalicylic acid per day cardiac prophylaxis permit . ) The subject allow take rescue medication ( acetaminophen ) pain study except 24 hour prior Baseline ( Day1 ) , Week 2 , Week 4 , Week 8 , Week 12/EOS , Followup assessment . A subject must willing avoid unaccustomed physical activity ( eg , start new weight lift routine ) duration study . A subject secondary OA knee OA low limb joint knee , opinion Investigator , could interfere pain functional assessment relate knee A subject OA knee Kellgren Lawrence Grade ≥3 determine Investigator local radiologist Screening A subject history total partial knee replacement , arthroplasty , knee surgery either knee A subject significant injury , judge Investigator , involve target knee within 6 month Screening . A subject skin lesion wound near knee treat Screening Day 1 prior first administration study medication A subject use opiate corticosteroid within 30 day Screening require treatment chronic opiate corticosteroids A subject intra articular injection corticosteroid , hyaluronic acid , viscosupplements ( eg , Synvisc® ) knee treat within 3 month Screening . A subject history significant hypersensitivity , intolerance , allergy ibuprofen , NSAIDs , aspirin , acetaminophen A subject active peptic ulceration 12 month prior Screening history gastrointestinal ( GI ) bleed within 5 year Screening A subject use anticoagulant ( except aspirin 325 mg/day cardiac prophylaxis ) month prior Screening A subject positive result fecal occult blood test Screening Day 1 prior first administration study medication A subject history chronic inflammatory disease ( rheumatoid arthritis , psoriatic arthritis , gouty arthritis ) , fibromyalgia , condition may affect target joint ( eg , osteonecrosis , chondrocalcinosis ) , asthma .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Phase 2 , Efficacy , Safety , Osteoarthritis</keyword>
</DOC>